Group Overview
With a 160-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. We have approximately 9 800 employees at 71 established offices in over 50 countries and we improve the health of patients in more than 150 countries through our high quality, affordable products.
Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments. Our key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products.
Our manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. We operate 23 manufacturing facilities across 15 sites and we hold international manufacturing approvals from some of the most stringent global regulatory agencies including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines.
Our business segments
We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments:
Commercial Pharmaceuticals
Contribution to Group revenue

Contribution to Group revenue
44%



Contribution to Group revenue
37%
Manufacturing
Contract and supply of chemical and biochemical APIs and finished dose form pharmaceuticals for third parties
Contribution to Group revenue
19%
Quick Facts
Established: 1850
Employees: Approximately 9 800
Share code: APN
JSE: Listed in 1998
Board of Directors
Stephen Saad (56)
Stephen Saad (56)
Qualification: CA(SA), PhD (Commerce) Honoris Causa
Appointment: January 1999
Classification: Executive director
Gus Attridge (59)
Gus Attridge (59)
Qualification: CA(SA)
Appointment: January 1999
Classification: Executive director
Kuseni Dlamini (52)
Kuseni Dlamini (52)
Qualification: MPhil (Oxon), BSocSci (Hons), (Natal), Global Leadership for the 21st
Century Programme (Harvard), Foundations for Leadership in the 21st Century (Yale)
Appointment: April 2012
Classification: Independent non-executive, Chairman
Linda de Beer (51)
Linda de Beer (51)
Qualification: CA(SA), MCom (Tax), CD(SA)
Appointment: July 2018
Classification: Independent non-executive
Ben Kruger (61)
Ben Kruger (61)
Qualification: BCom (Hons), CA(SA), Advanced Programme in Management (Harvard Business School)
Appointment: April 2019
Classification: Lead Independent non-executive
Themba Mkhwanazi (50)
Themba Mkhwanazi (50)
Qualification: B.Eng (Hons)
Appointment: July 2018
Classification: Independent non-executive
Chris Mortimer (59)
Chris Mortimer (59)
Qualification: BA, LLB
Appointment: January 1999
Classification: Non-executive
Babalwa Ngonyama (46)
Babalwa Ngonyama (46)
Qualification: CA(SA), MBA, Higher Diploma in Banking Law (RAU)
Appointment: April 2016
Classification: Independent non-executive
David Redfern (54)
David Redfern (54)
Qualification: BSc (Hons), CA
Appointment: February 2015
Classification:Non-executive (British)
Sindi Zilwa (53)
Sindi Zilwa (53)
Qualification: CA(SA), CD(SA), Advanced Taxation Certificate (UNISA), Advanced
Diploma in Financial Planning (UOFS) and Advanced Diploma in Banking (RAU)
Appointment: September 2006
Classification: Independent non-executive